As of September 1, A-share 457 pharmaceutical and biological enterprises have disclosed half-yearly report (Shenwan industry classification, the same below), the first half of this year, the pharmaceutical and biological industry to achieve a total operating income of 1.21 trillion yuan, an increase of 10.28% year-on-year; attributable to the shareholders of the parent company's net profit of 133.020 billion yuan, an increase of 7.32% year-on-year. Among them, the six subsectors (according to the Shenwan secondary industry classification), medical services and medical devices shine, revenue, net profit growth rate exceeded the industry's overall growth rate.
In addition to sustained growth in performance, the pharmaceutical and biological industry R & D expenses also hit a new high of 48.138 billion yuan, it is worth mentioning that in the first half of this year, A-share *** there are five pharmaceutical companies R & D expenses exceeded 1 billion yuan, of which four are innovative drug companies.
Two big track performance growth rate in the front
In the first half of this year, the pharmaceutical industry performance as a whole to achieve faster growth. Data show that in the first half of this year, the pharmaceutical and biological industries to achieve total operating income of 1.21 trillion yuan, an increase of 10.28%; attributable to shareholders of the parent company's net profit of 133.020 billion yuan, an increase of 7.32%.
The Economic Reference News reporter noted that in the first half of this year, in the pharmaceutical and biological industry, six subsectors, the performance of each plate varies.
Which, medical services, medical devices, biological products revenue growth rate higher than the industry's overall growth rate, respectively, 40.28%, 30.16%, 18.89%, pharmaceutical business, chemical pharmaceuticals, traditional Chinese medicine growth rate is lower than the industry's growth rate, respectively, 6.03%, 3.53%, 1.61%; from the mother of the net profit point of view, in the first half of this year, only the two major medical services, medical equipment Segment net profit growth rate higher than the industry as a whole, respectively, 77.13%, 29.52%, while the chemical pharmaceutical, pharmaceutical business, traditional Chinese medicine and biological products net profit growth rate are lower than the industry growth rate, respectively -4.25%, -4.98%, -14.35%, -40.24%.
See, in the first half of this year, medical services and medical devices, two major performance is relatively bright, revenue, net profit growth rate of the industry as a whole over the growth rate, and ranked at the forefront of the industry. However, compared with the growth rate of the same period last year, medical services plate revenue growth rate fell 1.19 percentage points year-on-year, net profit growth rate rose 32.16 percentage points year-on-year, medical equipment plate revenue, net profit growth rate fell 15.68 percentage points, 43.69 percentage points.
The Economic Reference News reporter noted that in the four major segments of medical services (according to the Shenwan three-tier industry classification), in the first half of this year, medical research and development outsourcing, diagnostic services, hospitals, other medical services revenue growth rate of 71.08%, 52.26%, -4.67%, 10.40%, of which, the CRO company Boteng shares, Kelaiyin, Pharmacare and so on. Performance growth rate are at the forefront of the plate, at the same time, Lanwei medicine, Dean Diagnostics, Jinwei medicine and other diagnostic services companies have also achieved substantial growth in performance.
Rapid growth in research and development costs
In addition to performance indicators, the pharmaceutical industry's R & D investment is also a concern. Data show that in the first half of this year, the pharmaceutical and biological industry R & D expenses totaled 48.138 billion yuan, an increase of 18.82% year-on-year, the R & D expenditure rate of 3.98%, up 0.28 percentage points.
However, in the first half of this year, in the pharmaceutical and biological industry six subsectors, the R & D investment in each sector varies.
First of all, from the R & D expenses, the first half of this year, the six major segments of the expense scale have increased, chemical pharmaceuticals, biologics, medical devices, traditional Chinese medicine, medical services, pharmaceutical business R & D expenses were 17.868 billion yuan, 11.745 billion yuan, 9.921 billion yuan, 4.179 billion yuan, 3.214 billion yuan, 1.212 billion yuan, respectively, year-on-year growth of 7.97%, 20.98%, 37.02%, 16.27%, 44.95%, 0.65%.
At the same time, from the R & D expense rate, biological products, chemical pharmaceuticals, medical devices R & D expense rate is higher than the industry as a whole, respectively, 15.26%, 6.96%, 5.95%, medical services, traditional Chinese medicine, pharmaceutical business is lower than the industry's overall value of 3.72%, 2.44%, 0.27%, respectively; it is worth mentioning that biological products, chemical pharmaceuticals, Medical devices R&D expense rate of 0.25 percentage points, 0.28 percentage points, 0.29 percentage points, respectively, compared with the same period last year, have increased.
The Economic Reference News reporter noted that in the first half of this year, innovative drug companies still high investment in research and development. Data show that in the first half of this year, Shenwan pharmaceutical and biological industry **** there are five companies with R & D expenses of more than 1 billion yuan, respectively, for Paizi Shenzhou, Hengrui Medicine, Fosun Pharmaceuticals, Myriad Medical, Junshi Biological, R & D expenses were 5.016 billion yuan, 2.184 billion yuan, 1.818 billion yuan, 1.350 billion yuan, 1.062 billion yuan, of which in addition to the Myriad Medical the remaining four are all innovative drug company ; and from the R & D investment ratio, Yahong Pharmaceutical, Shouzhu Pharmaceutical Holdings, Alliance Pharmaceuticals and other innovative drug companies R & D investment accounted for more than 300% of the industry's forefront.
If you want to know more real-time financial news, welcome to follow us.